ME01926B - 6-am in0-2-{[(1s)-1-meti lbuti l]oksi }-9-[5-(1-piperidinil) pentil]-7,9-di hidro-8h- purin-8-0n maleat - Google Patents
6-am in0-2-{[(1s)-1-meti lbuti l]oksi }-9-[5-(1-piperidinil) pentil]-7,9-di hidro-8h- purin-8-0n maleatInfo
- Publication number
- ME01926B ME01926B MEP-2014-154A MEP15414A ME01926B ME 01926 B ME01926 B ME 01926B ME P15414 A MEP15414 A ME P15414A ME 01926 B ME01926 B ME 01926B
- Authority
- ME
- Montenegro
- Prior art keywords
- compound
- dihydro
- oxy
- pentyl
- purin
- Prior art date
Links
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 title 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 12
- 150000002688 maleic acid derivatives Chemical class 0.000 claims 7
- LFMPVTVPXHNXOT-HNNXBMFYSA-N 6-amino-2-[(2s)-pentan-2-yl]oxy-9-(5-piperidin-1-ylpentyl)-7h-purin-8-one Chemical compound C12=NC(O[C@@H](C)CCC)=NC(N)=C2NC(=O)N1CCCCCN1CCCCC1 LFMPVTVPXHNXOT-HNNXBMFYSA-N 0.000 claims 6
- 208000026935 allergic disease Diseases 0.000 claims 6
- 239000000427 antigen Substances 0.000 claims 4
- 102000036639 antigens Human genes 0.000 claims 4
- 108091007433 antigens Proteins 0.000 claims 4
- 208000027866 inflammatory disease Diseases 0.000 claims 4
- 230000002757 inflammatory effect Effects 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 208000035473 Communicable disease Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 206010039085 Rhinitis allergic Diseases 0.000 claims 2
- 201000010105 allergic rhinitis Diseases 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 230000004968 inflammatory condition Effects 0.000 claims 2
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 239000000969 carrier Substances 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000002163 immunogen Effects 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
- 239000012646 vaccine adjuvant Substances 0.000 claims 1
- 229940124931 vaccine adjuvant Drugs 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Otolaryngology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30301010P | 2010-02-10 | 2010-02-10 | |
| PCT/EP2011/051830 WO2011098452A1 (en) | 2010-02-10 | 2011-02-08 | 6-amino-2-{ [ (1s)-1-methylbutyl] oxy}-9-[5-(1-piperidinyl)-7,9-dihydro-8h-purin-8-one maleate |
| EP11709025.8A EP2534149B1 (en) | 2010-02-10 | 2011-02-08 | 6-amino-2-{[(1s)-1-methylbutyl]oxy}-9-[5-(1-piperidinyl)pentyl]-7,9-dihydro-8h-purin-8-one maleate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME01926B true ME01926B (me) | 2015-05-20 |
Family
ID=43836817
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2014-154A ME01926B (me) | 2010-02-10 | 2011-02-08 | 6-am in0-2-{[(1s)-1-meti lbuti l]oksi }-9-[5-(1-piperidinil) pentil]-7,9-di hidro-8h- purin-8-0n maleat |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US8703754B2 (OSRAM) |
| EP (1) | EP2534149B1 (OSRAM) |
| JP (1) | JP5922587B2 (OSRAM) |
| KR (1) | KR101773541B1 (OSRAM) |
| CN (1) | CN102753553B (OSRAM) |
| AU (1) | AU2011214468B2 (OSRAM) |
| BR (1) | BR112012018904A2 (OSRAM) |
| CA (1) | CA2786973C (OSRAM) |
| DK (1) | DK2534149T3 (OSRAM) |
| EA (1) | EA021048B1 (OSRAM) |
| ES (1) | ES2525826T3 (OSRAM) |
| HR (1) | HRP20141258T1 (OSRAM) |
| IL (1) | IL220845A (OSRAM) |
| ME (1) | ME01926B (OSRAM) |
| MX (1) | MX2012009316A (OSRAM) |
| PL (1) | PL2534149T3 (OSRAM) |
| PT (1) | PT2534149E (OSRAM) |
| RS (1) | RS53745B1 (OSRAM) |
| SG (1) | SG182471A1 (OSRAM) |
| SI (1) | SI2534149T1 (OSRAM) |
| SM (1) | SMT201400196B (OSRAM) |
| WO (1) | WO2011098452A1 (OSRAM) |
| ZA (1) | ZA201205995B (OSRAM) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA103195C2 (uk) | 2008-08-11 | 2013-09-25 | Глаксосмитклайн Ллк | Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань |
| RU2015151857A (ru) | 2008-12-02 | 2019-01-15 | Уэйв Лайф Сайенсес Джапан, Инк. | Способ синтеза модифицированных по атому фосфора нуклеиновых кислот |
| MX342945B (es) | 2009-07-06 | 2016-10-18 | Ontorii Inc * | Profármacos de ácido nucleico novedosos y métodos de uso de los mismos. |
| CA2777824C (en) | 2009-10-22 | 2016-11-29 | Gilead Sciences, Inc. | Derivatives of purine or deazapurine useful for the treatment of (inter alia) viral infections |
| US10428019B2 (en) | 2010-09-24 | 2019-10-01 | Wave Life Sciences Ltd. | Chiral auxiliaries |
| EP3248982A1 (en) | 2011-07-19 | 2017-11-29 | Wave Life Sciences Ltd. | Thiosulfonate reagents for the synthesis of functionalized nucleic acids |
| LT2734186T (lt) * | 2011-07-22 | 2018-12-10 | Glaxosmithkline Llc | Kompozicija |
| CA2879023C (en) | 2012-07-13 | 2017-03-28 | Wave Life Sciences Japan | Asymmetric auxiliary group |
| CA2879066C (en) * | 2012-07-13 | 2019-08-13 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant |
| CN104661664B (zh) | 2012-07-13 | 2020-07-03 | 波涛生命科学有限公司 | 手性控制 |
| MX359671B (es) | 2012-08-24 | 2018-10-05 | Glaxosmithkline Llc Star | Compuestos de pirazolopiridina. |
| JP6228223B2 (ja) | 2012-11-20 | 2017-11-08 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ | 新規化合物 |
| BR112015011439A2 (pt) | 2012-11-20 | 2017-07-11 | Glaxosmithkline Llc | composto, composição farmacêutica, composição de vacina, e, uso de um composto |
| RU2643371C2 (ru) | 2012-11-20 | 2018-02-01 | ГЛАКСОСМИТКЛАЙН ЭлЭлСи | Новые соединения |
| US10144933B2 (en) | 2014-01-15 | 2018-12-04 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator |
| US10322173B2 (en) | 2014-01-15 | 2019-06-18 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent |
| JPWO2015108048A1 (ja) | 2014-01-15 | 2017-03-23 | 株式会社新日本科学 | 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤 |
| MX2016009290A (es) | 2014-01-16 | 2017-02-28 | Wave Life Sciences Ltd | Diseño quiral. |
| WO2016033540A1 (en) * | 2014-08-29 | 2016-03-03 | Corium International, Inc. | Microstructure array for delivery of active agents |
| US10584125B2 (en) * | 2014-11-13 | 2020-03-10 | Glaxosmithkline Biologicals Sa | Adenine derivatives which are useful in the treatment of allergic diseases or other inflammatory conditions |
| US12130267B2 (en) * | 2018-11-28 | 2024-10-29 | Shimadzu Corporation | Analyzing method for azo compound |
| KR20250106231A (ko) | 2023-12-29 | 2025-07-09 | (주)셀트리온 | 안정한 약제학적 제제 |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB427857A (en) | 1934-08-02 | 1935-05-01 | Newsum Sons & Company Ltd H | A new or improved system of construction for skeleton structures, particularly vehicle body frames and door frames |
| NZ263686A (en) | 1993-03-17 | 1997-09-22 | Minnesota Mining & Mfg | Medicinal aerosol with dispersing aid derived from a hydroxy acid, an amino acid and/or a mercapto acid |
| US6126919A (en) | 1997-02-07 | 2000-10-03 | 3M Innovative Properties Company | Biocompatible compounds for pharmaceutical drug delivery systems |
| EP1065213A3 (en) | 1999-07-02 | 2003-11-05 | Japan Tobacco Inc. | HCV polymerase suitable for crystal structure analysis and method for using the enzyme |
| SK13752001A3 (sk) | 1999-12-27 | 2002-07-02 | Japan Tobacco, Inc. | Zlúčeniny s fúzovanými kruhmi a ich použitie ako liečiv |
| US6448281B1 (en) | 2000-07-06 | 2002-09-10 | Boehringer Ingelheim (Canada) Ltd. | Viral polymerase inhibitors |
| US6310224B1 (en) | 2001-01-19 | 2001-10-30 | Arco Chemical Technology, L.P. | Epoxidation catalyst and process |
| HUP0400726A3 (en) | 2001-01-22 | 2007-05-29 | Merck & Co Inc | Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase |
| IL157940A0 (en) | 2001-03-19 | 2004-03-28 | Ono Pharmaceutical Co | Drugs containing triazaspiro [5.5] undecane derivatives as the active ingredient |
| AR035543A1 (es) | 2001-06-26 | 2004-06-16 | Japan Tobacco Inc | Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con |
| CA2448737C (en) | 2001-07-20 | 2010-06-01 | Boehringer Ingelheim (Canada) Ltd. | Viral polymerase inhibitors |
| EP1497469A4 (en) | 2002-04-04 | 2005-06-08 | Achillion Pharmaceuticals Inc | TEST FOR ASSESSING THE ACTIVITY OF COMPOUNDS AGAINST HCV USING A NOVEL DETECTION SYSTEM IN THE HCV REPLICIC |
| DOP2003000641A (es) | 2002-05-10 | 2003-11-15 | Pfizer | Inhibidores de las arn polimerasa dependiente de arn del virus de las hepatitis c y composiciones y tratamiento que los usan |
| WO2004037818A1 (en) | 2002-10-24 | 2004-05-06 | Glaxo Group Limited | 1-acyl-pyrrolidine derivatives for the treatment of viral infections |
| ES2311755T3 (es) | 2002-12-13 | 2009-02-16 | Smithkline Beecham Corporation | Compuestos de ciclohexilo como antagonistas de ccrs. |
| AU2003300952A1 (en) | 2002-12-13 | 2004-07-09 | Smithkline Beecham Corporation | Indane compounds as ccr5 antagonists |
| ES2298627T3 (es) | 2002-12-13 | 2008-05-16 | Smithkline Beecham Corporation | Compuestos de ciclopropilo como antagonistas de ccr5. |
| DE60322423D1 (de) | 2002-12-13 | 2008-09-04 | Smithkline Beecham Corp | Pyrrolidin- und azetidinverbindungen alsccr5-antagonisten |
| ES2312856T3 (es) | 2002-12-13 | 2009-03-01 | Smithkline Beecham Corporation | Compuestos heterociclicos como antagonistas de ccr5. |
| CN1744899A (zh) | 2002-12-13 | 2006-03-08 | 史密丝克莱恩比彻姆公司 | 作为ccr5拮抗剂的哌啶衍生物 |
| US7223785B2 (en) | 2003-01-22 | 2007-05-29 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
| US7098231B2 (en) | 2003-01-22 | 2006-08-29 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
| US7148226B2 (en) | 2003-02-21 | 2006-12-12 | Agouron Pharmaceuticals, Inc. | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same |
| WO2005014543A1 (ja) | 2003-08-06 | 2005-02-17 | Japan Tobacco Inc. | 縮合環化合物及びそのｈｃｖポリメラーゼ阻害剤としての利用 |
| CN102028994B (zh) | 2003-11-03 | 2013-04-24 | 葛兰素集团有限公司 | 流体分配装置 |
| IN2012DN04853A (OSRAM) | 2004-02-20 | 2015-09-25 | Boehringer Ingelheim Int | |
| EP1748991A1 (en) | 2004-04-28 | 2007-02-07 | Arrow Therapeutics Limited | Morpholinylanilinoquinazo- line derivatives for use as antiviral agents |
| US7153848B2 (en) | 2004-08-09 | 2006-12-26 | Bristol-Myers Squibb Company | Inhibitors of HCV replication |
| CA2577525C (en) | 2004-08-18 | 2010-03-30 | Pfizer Inc. | Inhibitors of hepatitis c virus rna-dependent rna polymerase, and compositions and treatments using the same |
| US20060045885A1 (en) | 2004-08-27 | 2006-03-02 | Kedl Ross M | Method of eliciting an immune response against HIV |
| GB0423673D0 (en) | 2004-10-25 | 2004-11-24 | Glaxo Group Ltd | Compounds |
| KR20080019213A (ko) | 2005-05-09 | 2008-03-03 | 아칠리온 파르마세우티칼스 인코포레이티드 | 티아졸 화합물 및 그 사용방법 |
| EP1939198A4 (en) * | 2005-09-22 | 2012-02-15 | Dainippon Sumitomo Pharma Co | NEW ADENINE CONNECTION |
| GB0610666D0 (en) | 2006-05-30 | 2006-07-05 | Glaxo Group Ltd | Fluid dispenser |
| TW200843779A (en) | 2007-02-19 | 2008-11-16 | Smithkline Beecham Corp | Compounds |
| WO2008114008A1 (en) * | 2007-03-19 | 2008-09-25 | Astrazeneca Ab | 9-substituted-8-oxo-adenine compounds as toll-like receptor (tlr7 ) modulators |
| PE20091156A1 (es) * | 2007-12-17 | 2009-09-03 | Astrazeneca Ab | Sales de (3-{[[3-(6-amino-2-butoxi-8-oxo-7,8-dihidro-9h-purin-9-il)propil](3-morfolin-4-ilpropil)amino]metil}fenil)acetato de metilo |
| US8777708B2 (en) | 2008-06-27 | 2014-07-15 | Microsoft Corporation | Targeting control in a simulated environment |
| UA103195C2 (uk) * | 2008-08-11 | 2013-09-25 | Глаксосмитклайн Ллк | Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань |
-
2011
- 2011-02-08 BR BR112012018904-2A patent/BR112012018904A2/pt not_active IP Right Cessation
- 2011-02-08 EP EP11709025.8A patent/EP2534149B1/en active Active
- 2011-02-08 ME MEP-2014-154A patent/ME01926B/me unknown
- 2011-02-08 PT PT117090258T patent/PT2534149E/pt unknown
- 2011-02-08 EA EA201290631A patent/EA021048B1/ru not_active IP Right Cessation
- 2011-02-08 PL PL11709025T patent/PL2534149T3/pl unknown
- 2011-02-08 US US13/578,020 patent/US8703754B2/en not_active Expired - Fee Related
- 2011-02-08 CA CA2786973A patent/CA2786973C/en not_active Expired - Fee Related
- 2011-02-08 WO PCT/EP2011/051830 patent/WO2011098452A1/en not_active Ceased
- 2011-02-08 AU AU2011214468A patent/AU2011214468B2/en not_active Ceased
- 2011-02-08 ES ES11709025.8T patent/ES2525826T3/es active Active
- 2011-02-08 KR KR1020127023687A patent/KR101773541B1/ko not_active Expired - Fee Related
- 2011-02-08 SG SG2012051140A patent/SG182471A1/en unknown
- 2011-02-08 MX MX2012009316A patent/MX2012009316A/es active IP Right Grant
- 2011-02-08 HR HRP20141258AT patent/HRP20141258T1/hr unknown
- 2011-02-08 RS RS20150005A patent/RS53745B1/sr unknown
- 2011-02-08 CN CN201180009082.0A patent/CN102753553B/zh not_active Expired - Fee Related
- 2011-02-08 SI SI201130364T patent/SI2534149T1/sl unknown
- 2011-02-08 JP JP2012552369A patent/JP5922587B2/ja active Active
- 2011-02-08 DK DK11709025.8T patent/DK2534149T3/da active
-
2012
- 2012-07-10 IL IL220845A patent/IL220845A/en not_active IP Right Cessation
- 2012-08-08 ZA ZA2012/05995A patent/ZA201205995B/en unknown
-
2014
- 2014-12-30 SM SM201400196T patent/SMT201400196B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2011214468B2 (en) | 2015-05-28 |
| PT2534149E (pt) | 2014-12-23 |
| SG182471A1 (en) | 2012-08-30 |
| EP2534149B1 (en) | 2014-10-15 |
| HRP20141258T1 (hr) | 2015-02-27 |
| RS53745B1 (sr) | 2015-06-30 |
| CA2786973A1 (en) | 2011-08-18 |
| EA201290631A1 (ru) | 2013-03-29 |
| PL2534149T3 (pl) | 2015-03-31 |
| KR101773541B1 (ko) | 2017-08-31 |
| SI2534149T1 (sl) | 2015-02-27 |
| DK2534149T3 (da) | 2015-01-05 |
| CN102753553A (zh) | 2012-10-24 |
| US8703754B2 (en) | 2014-04-22 |
| IL220845A (en) | 2016-08-31 |
| WO2011098452A1 (en) | 2011-08-18 |
| ZA201205995B (en) | 2014-01-29 |
| JP2013519645A (ja) | 2013-05-30 |
| CA2786973C (en) | 2018-04-10 |
| SMT201400196B (it) | 2015-01-15 |
| ES2525826T3 (es) | 2014-12-30 |
| MX2012009316A (es) | 2012-09-12 |
| BR112012018904A2 (pt) | 2020-09-01 |
| EP2534149A1 (en) | 2012-12-19 |
| US20120308609A1 (en) | 2012-12-06 |
| CN102753553B (zh) | 2016-03-30 |
| EA021048B1 (ru) | 2015-03-31 |
| JP5922587B2 (ja) | 2016-05-24 |
| AU2011214468A1 (en) | 2012-08-09 |
| KR20120135408A (ko) | 2012-12-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ME01926B (me) | 6-am in0-2-{[(1s)-1-meti lbuti l]oksi }-9-[5-(1-piperidinil) pentil]-7,9-di hidro-8h- purin-8-0n maleat | |
| ME02274B (me) | DERIVATI PURINA ZA UPOTREBU U LEČENJU ALERGIJSKIH, INFLAMATORNIH l INFEKTIVNIH BOLESTI | |
| JP2013519645A5 (OSRAM) | ||
| BR112014001798A2 (pt) | compostos de tetraciclina 9-aminometila substituídos | |
| MX374497B (es) | Inhibidor del antígeno de superficie del virus de la hepatitis b. | |
| HRP20180237T4 (hr) | Metode za liječenje hcv-a | |
| CA2925624C (en) | Substituted nicotinimide inhibitors of btk and their preparation and use in the treatment of cancer, inflammation and autoimmune disease | |
| ME02547B (me) | Inhibitori hepatitis c virusa | |
| HRP20171512T1 (hr) | Derivati betulina | |
| CY1120342T1 (el) | Ανταγωνιστης πολυκυκλικου lpa1 και χρησεις εξ' αυτου | |
| RU2015117251A (ru) | Новые соединения | |
| EA201592250A1 (ru) | Пиразолопирролидиновые производные и их применение в лечение заболеваний | |
| NO20063693L (no) | Forbindelse og metode for anvendelse | |
| MX2013004817A (es) | Enfermedad inflamatoria. | |
| JP2010270124A5 (OSRAM) | ||
| JP2014521735A5 (OSRAM) | ||
| EA201391758A1 (ru) | Спрессованная сердцевина для фармацевтической композиции, содержащая органические кислоты | |
| EA201200618A1 (ru) | Производные хроменона с антиопухолевой активностью | |
| WO2012125926A3 (en) | Tetracyclic xanthene derivatives and methods of use thereof for the treatment of viral diseases | |
| EP2581376A4 (en) | MATRINIC ACID / MATRINE DERIVATIVES AND METHODS OF PREPARATION AND USES THEREOF | |
| BR112013026355A2 (pt) | compostos de pirazolo[3,4-b]piridina tri- e tetracíclicos como agente antineoplásico | |
| BRPI0720667A8 (pt) | Métodos de administração de vacina | |
| ITMI20020808A1 (it) | Procedimento per la preparazione di una sospensione sterile di particelle di beclometasone dipropionato da somministrare per inalazione | |
| RU2016112257A (ru) | Композиция для лечения гипертензии и/или фиброза | |
| RU2013157398A (ru) | Композиция |